Dr. Weinberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Philadelphia, PA 19104Phone+1 800-789-7366Fax+1 215-349-5915
Education & Training
- Rockefeller UniversityMS, Clinical Investigation, 2016
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2012
- University of Maryland School of MedicineClass of 2009
- University of MarylandMD, 2009
- Princeton UniversityAB, 2003
Certifications & Licensure
- PA State Medical License 2016 - 2024
- NY State Medical License 2011 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Clinical Trials
- A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) Start of enrollment: 2023 May 23
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis Start of enrollment: 2023 Jun 13
- FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study Start of enrollment: 2022 Dec 15
Publications & Presentations
PubMed
- Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population.K Rajender Reddy, Ethan M Weinberg, Stevan A Gonzalez, Manhal J Izzy, Douglas A Simonetto
Liver Transplantation. 2024-10-01 - Candidates for liver transplant evaluated at satellite clinics at a large academic transplant center are less likely to be waitlisted.Kevin Tang, Jason J Lee, Ethan Weinberg, Marina Serper, Therese Bittermann
Liver Transplantation. 2024-10-01 - Ursodeoxycholic acid for the treatment of hepatic sarcoid: A pre-post pilot study.Ethan Weinberg, Aimee Stonelake, Kelly Borges, Emily Toal, Sevda Aghayeva
Clinical and Experimental Hepatology. 2024-09-01
Press Mentions
- PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD - the Liver Meeting® 2024November 18th, 2024
- PharmaIN to Present Promising Interim Data from Its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at the Liver Meeting® 2024October 16th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: